1. Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes
- Author
-
Praveen Patel, Rory Collins, Richard Peto, Mark Davies, Sanjiv Banerjee, David Simpson, John Anderson, Louise Bowman, Peter Scanlon, Amanda Adler, Andrew Farmer, Helen Cook, Laura Evans, Elizabeth Williamson, Louis Bolter, Jane Armitage, Peter Sandercock, Richard Gray, Nilesh Samani, Tasso Gazis, Richard Haynes, Arun Sachdev, Eric Wu, Elizabeth Wincott, Peter Sleight, Colin Baigent, Marion Mafham, Sarah Parish, Gavin Brown, Susan Hurley, Lynne Allsop, William Stevens, Theingi Aung, Allen Young, Emily Sammons, Georgina Buck, Imen Hammami, Jill Barton, Jonathan Bodansky, Roger McPherson, Lucy Fletcher, Murphy Kevin, Ryonfa Lee, Sandra Pickworth, Monica Willett, Michael Lay, Ola Murawska, Karen Melham, Jonathan Latham-Mollart, Anna Brewer, Mike Olson, Jude Kay, Alisha Griffiths, Helen Clayton, Philip Kirby, Mike Pennington, Dominic Clarke, Jenny Anslow, Alex Hallam, Jenny Witts, Sarah Egan, Alex Wharton, Amy Derbyshire, Katherine Hepplestone, Sujit Mithra, Su Oliver, Pauline Wiatrak-Olszewska, Kelly Alvey, Nick Gregory, Priyai Parkinson, Prema Maharajan, Rachel McFee, Donna Sowter, John Featonby, Richard Furnival, Helen Lipinski, Hazel Benjamin, Tanisha McAfee, Emma Payne Payne, and Liz Still
- Subjects
Medicine - Abstract
Purpose Aspirin and omega-3 fatty acids (FAs) are potential disease modifiers of age-related macular degeneration (AMD), but previous studies have produced inconsistent findings. Randomised evidence for the efficacy and safety of aspirin and omega-3 FAs on AMD is presented in this study.Design ASCEND-Eye is a substudy of eye effects in the 2×2 factorial design ASCEND (A Study of Cardiovascular Events iN Diabetes) double-blind, randomised, placebo-controlled trial for the primary prevention of cardiovascular events. Reports of AMD diagnoses were sourced from 6 monthly ASCEND follow-up questionnaires and a Visual Function Questionnaire.Participants 15 480 UK adults at least 40 years of age with diabetes but no evident cardiovascular disease.Interventions 100 mg aspirin daily versus placebo and, separately, 1 g omega-3 FAs daily versus placebo.Main outcome measure The first post-randomisation reports of AMD.Results During 7.4 years of follow-up, 122 (1.6%) participants randomised to aspirin were reported as having AMD, compared with 138 (1.8%) randomised to placebo (rate ratio 0.88; 95% CI 0.69 to 1.12; p=0.31). AMD occurred in 130 (1.7%) participants randomised to omega-3 FAs, compared with 130 (1.7%) randomised to placebo (rate ratio 0.99; 95% CI 0.78 to 1.27; p=0.99).Conclusion No clinically-meaningful effects of aspirin or omega-3 FAs on AMD were found. Although the study had very limited statistical power to detect clinically relevant effects, these data overcome some methodological limitations of previous observational studies, providing randomised evidence of both treatments on AMD, which could contribute to future meta-analyses.Trial registration number ISRCTN60635500 and NCT00135226.
- Published
- 2025
- Full Text
- View/download PDF